News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...
Moderna stock jumped 4.93% to $27.87 in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine requiring only one-fifth the dose of the company's current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback